Hepatitis C Blood Test: Normal Ranges, Causes & What Your Results Mean

What Is Hepatitis C?

Hepatitis C is a blood-borne viral infection caused by the hepatitis C virus (HCV) that primarily affects the liver. The hepatitis C blood test typically measures antibodies to the virus (anti-HCV), which indicate whether your immune system has ever encountered HCV. Unlike hepatitis A and B, there is currently no vaccine available for hepatitis C.

Hepatitis C is often called a "silent" infection because the majority of people, approximately 80%, experience no symptoms during the acute phase. Without testing, the infection can go undetected for years or even decades whilst progressively damaging the liver. By the time symptoms appear, significant liver damage may have already occurred.

The virus is transmitted primarily through blood-to-blood contact. Historically, the most common route of transmission in the UK was through contaminated blood products (before screening was introduced in 1991) and sharing of needles among people who inject drugs. Other less common routes include needlestick injuries, tattooing or body piercing with non-sterile equipment, and rarely, sexual transmission or mother-to-child transmission during childbirth.

In the UK, Public Health England estimates that approximately 118,000 people are living with chronic hepatitis C, with around 40% unaware of their infection. The good news is that hepatitis C is now curable in over 95% of cases with direct-acting antiviral (DAA) therapy, making early detection more important than ever. The NHS is committed to eliminating hepatitis C as a public health threat, in line with the World Health Organisation's 2030 target.

Why Is Hepatitis C Tested?

Hepatitis C testing is recommended for several clinical and public health reasons:

• At-risk population screening: NICE and Public Health England recommend targeted testing for individuals at increased risk, including current or former people who inject drugs, recipients of blood products before September 1991, and people born in countries with high HCV prevalence.
• Unexplained liver disease: Elevated liver enzymes (ALT, AST), abnormal liver imaging, or clinical signs of liver disease (jaundice, ascites, spider naevi) prompt hepatitis C testing as part of the diagnostic workup.
• Blood and organ donation screening: All blood donations in the UK are tested for anti-HCV to prevent transfusion-transmitted infection.
• HIV co-infection screening: NICE recommends hepatitis C testing for all HIV-positive individuals, as co-infection is common and accelerates liver disease progression.
• Occupational exposure: Following needlestick injuries or other blood exposures in healthcare settings, HCV testing of both the source and exposed individual guides management.
• Prison health screening: The prevalence of hepatitis C is significantly higher in the prison population. Opt-out testing is offered in UK prisons as part of the NHS elimination strategy.
• Before immunosuppressive therapy: Screening prior to chemotherapy or biological therapy identifies infections that could reactivate or complicate treatment.

Normal Ranges

Hepatitis C testing involves two stages: an initial antibody screen and, if positive, a confirmatory RNA test.

Test	Result	Interpretation
Anti-HCV antibody	Non-reactive (Negative)	No evidence of HCV exposure; no current or past infection
Anti-HCV antibody	Reactive (Positive)	HCV exposure detected; does not distinguish past from current infection
HCV RNA (PCR)	Not detected	No active viral replication; either cleared infection or successful treatment
HCV RNA (PCR)	Detected	Active hepatitis C infection; virus is replicating and treatment is indicated

For patients with confirmed active infection, additional testing includes:

Test	Purpose	Clinical Relevance
HCV RNA quantitative (viral load)	Measures amount of virus (IU/mL)	Guides treatment response monitoring
HCV genotype	Identifies viral strain (1-6)	Some DAA regimens are genotype-specific; pan-genotypic options now preferred
FibroScan or APRI score	Assesses liver fibrosis stage	Determines urgency of treatment and cirrhosis surveillance needs

It is important to understand that anti-HCV antibodies persist for life, even after successful treatment and viral clearance. A positive antibody test therefore does not necessarily mean active infection - only HCV RNA testing can confirm whether the virus is still present.

What Do Positive Hepatitis C Results Mean?

A positive hepatitis C test has different implications depending on which test is positive:

• Anti-HCV positive, RNA positive: This confirms active hepatitis C infection. The virus is replicating in your body and can cause ongoing liver damage. You are potentially infectious to others through blood-to-blood contact. Treatment with DAA therapy is recommended.
• Anti-HCV positive, RNA negative: This indicates past exposure to HCV that has been cleared, either spontaneously (approximately 20-25% of acute infections resolve without treatment) or through successful antiviral therapy. You are not currently infected and are not infectious.
• Chronic hepatitis C: If HCV RNA remains detectable for more than 6 months after initial infection, the condition is classified as chronic. Without treatment, chronic hepatitis C can lead to progressive liver fibrosis over 20-30 years.
• Risk of cirrhosis: Approximately 10-20% of people with untreated chronic hepatitis C develop cirrhosis within 20-30 years. Risk factors for faster progression include alcohol consumption, co-infection with HIV or hepatitis B, male sex, and older age at infection.
• Hepatocellular carcinoma risk: Patients with HCV-related cirrhosis have a 1-5% annual risk of developing liver cancer. Six-monthly ultrasound surveillance is recommended for patients with cirrhosis, even after successful viral eradication.
• Extrahepatic manifestations: Chronic hepatitis C is associated with conditions outside the liver, including mixed cryoglobulinaemia, membranoproliferative glomerulonephritis, porphyria cutanea tarda, non-Hodgkin lymphoma, and type 2 diabetes.
• Potential for reinfection: Unlike hepatitis B, clearing hepatitis C does not confer lasting immunity. Individuals with ongoing risk factors (such as injecting drug use) can be reinfected and should be tested regularly.

What Do Negative Hepatitis C Results Mean?

A negative anti-HCV antibody result generally indicates:

• No HCV exposure: The most common interpretation - you have never been infected with hepatitis C. You are susceptible to infection if exposed.
• Window period: Antibodies to HCV take an average of 8-11 weeks to develop after infection (and occasionally up to 6 months). Testing during this "window period" may produce a false negative. If recent exposure is suspected, repeat testing at 12 and 24 weeks is recommended, or direct HCV RNA testing can detect infection within 1-2 weeks of exposure.
• Immunosuppression: Severely immunocompromised individuals (advanced HIV, organ transplant recipients, patients on haemodialysis) may fail to produce detectable antibodies despite active HCV infection. Direct HCV RNA testing should be used in these populations.
• Very early acute infection: In the first few weeks after exposure, before seroconversion, antibody tests will be negative. If acute hepatitis C is suspected clinically, HCV RNA testing is the appropriate investigation.
• False negative: Although modern anti-HCV assays have excellent sensitivity (greater than 99%), very rare false negatives can occur. Clinical context should guide the need for repeat testing.

How to Manage Your Hepatitis C Status

The management of hepatitis C has been transformed by the development of direct-acting antiviral (DAA) drugs, which cure over 95% of infections.

If You Have Active Hepatitis C

• Seek specialist referral: NICE recommends that all patients with confirmed active hepatitis C (RNA positive) are referred to hepatology or infectious disease services. Many areas now also offer treatment through community settings, GP practices, and drug services to improve access.
• Direct-acting antiviral therapy: Current first-line treatments include pan-genotypic regimens such as sofosbuvir/velpatasvir (Epclusa) or glecaprevir/pibrentasvir (Maviret), typically taken for 8-12 weeks. These oral medications have cure rates exceeding 95% with minimal side effects.
• Liver assessment: Before starting treatment, your specialist will assess the degree of liver fibrosis using FibroScan (transient elastography) or blood-based scores (APRI, FIB-4). This determines treatment urgency and the need for ongoing surveillance.
• Avoid alcohol: Alcohol accelerates liver fibrosis in hepatitis C. Complete abstinence is strongly recommended during and after treatment. If you need support with alcohol use, the NHS offers free specialist services.
• Protect your liver: Avoid hepatotoxic medications (including paracetamol in excess), maintain a healthy weight, and discuss any supplements or herbal remedies with your healthcare provider.
• Prevent transmission: Do not share needles, razors, toothbrushes, or other items that may carry blood. Inform healthcare providers of your status so appropriate precautions can be taken.

After Successful Treatment

• Sustained virological response (SVR): If HCV RNA is undetectable 12 weeks after completing treatment (SVR12), you are considered cured. The risk of relapse after achieving SVR12 is less than 1%.
• Ongoing surveillance if cirrhotic: Even after cure, patients with established cirrhosis require lifelong 6-monthly ultrasound surveillance for hepatocellular carcinoma, as the cancer risk persists.
• Reinfection prevention: If you have ongoing risk factors, take steps to reduce the chance of reinfection. Harm reduction services, including needle exchange programmes, are available across the UK.

When Should You Get Tested?

Consider hepatitis C testing if any of the following apply:

• You have ever injected drugs, even once or a long time ago
• You received a blood transfusion or blood products in the UK before September 1991
• You received medical or dental treatment in countries with poor infection control
• You were born in a country with high hepatitis C prevalence (Central Asia, East Asia, North Africa, Middle East)
• You are HIV positive
• You have unexplained elevated liver enzymes or liver disease
• You have had a tattoo or body piercing in an unregulated setting
• You are or have been in prison
• You have a sexual partner with hepatitis C
• You are a healthcare worker who has had a needlestick injury
• You were born to a mother with hepatitis C

The NHS hepatitis C elimination programme aims to diagnose and treat all infected individuals by 2030. If you think you may be at risk, getting tested is the first and most important step. Many NHS trusts now offer rapid point-of-care testing and community-based treatment to make the process as accessible as possible.

Which Lola Health Tests Include Hepatitis C?

Lola Health offers comprehensive blood testing to help you assess your liver health and infection status:

• Peak Insights - Our most detailed health panel, covering liver function markers and a wide range of biomarkers for a thorough health assessment.
• Vital Check — A detailed wellness assessment including essential liver markers to help identify potential health concerns.
• Core Health — An essential health check covering foundational biomarkers including liver function to monitor your overall wellbeing.

All Lola Health tests use venous blood draws performed by qualified phlebotomists for medical-grade accuracy. Results are reviewed by GP-certified professionals and delivered with personalised health recommendations.